Abstract
Patients with Marfan syndrome (MFS) develop thoracic aortic aneurysms as the aorta presents excessive elastin breaks, fibrosis, and vascular smooth muscle cell (vSMC) death due to mutations in the FBN1 gene. Despite elaborate vSMC to aortic endothelial cell (EC) signaling, the contribution of ECs to the development of aortic pathology remains largely unresolved. The aim of this study is to investigate the EC properties in Fbn1C1041G/+ MFS mice. Using en face immunofluorescence confocal microscopy, we showed that EC alignment with blood flow was reduced, EC roundness was increased, individual EC surface area was larger, and EC junctional linearity was decreased in aortae of Fbn1C1041G/+ MFS mice. This modified EC phenotype was most prominent in the ascending aorta and occurred before aortic dilatation. To reverse EC morphology, we performed treatment with resveratrol. This restored EC blood flow alignment, junctional linearity, phospho-eNOS expression, and improved the structural integrity of the internal elastic lamina of Fbn1C1041G/+ mice. In conclusion, these experiments identify the involvement of ECs and underlying internal elastic lamina in MFS aortic pathology, which could act as potential target for future MFS pharmacotherapies.
Subject terms: Cardiovascular diseases, Cellular imaging
Introduction
Marfan Syndrome (MFS) is an autosomal dominant disorder of the connective tissue that is caused by mutations in the FBN1 gene encoding fibrillin-11,2. MFS (OMIM: 154,700) is a systemic disease with an estimated prevalence of ~ 1:10.0003–5. The disease is manifested in the cardiovascular, skeletal, and ocular system. Most life-threatening cardiovascular complications are the dilatation of the aortic root and the ascending aorta, which may dissect or rupture6–8. To prevent rupture, long-term pharmacotherapies using β-blockers, angiotensin-II receptor blockers or by surgical interventions are performed as described in the medical guidelines9.
Fibrillin-1 is an important glycoprotein that forms microfibrils10,11. Mutations in the FBN1 gene decrease the availability of fibrillin-1 or alters its structure, interfering with proper microfibril formation12,13. Fibrillin-1 acts as a scaffold for elastic fiber formation, although microfibrils also occur independently of elastic fibers14. Besides its structural properties in the extracellular matrix (ECM), fibrillin-1 can sequester growth factors to regulate their local availability and activity, indicating the versatility of this protein11,15,16.
Extensive ECM-cell interactions are present in the aortic vessel wall that consists of an integrated network of various cell types supported by a durable matrix including elastin fibers and fibrillin-1 microfibrils. Microfibrils tether vascular smooth muscle cells (vSMCs) and endothelial cells (ECs) to the elastic fibers of the ECM17,18. Moreover, the Arg-Gly-Asp (RGD) motif of fibrillin-1 binds to a subset of integrins, the main element of cell-ECM adhesions, which regulates cell adhesion19,20. The integrin receptors bind to microfibrils that surround the elastin fibers to form a direct link between the ECM and the cellular cytoskeleton. The elastin-contractile units in the vessel wall can directly affect cellular signaling pathways, resulting in changes in cellular behavior such as cell adhesion, shape remodeling, migration, or proliferation21–23.
Moreover, the vascular system is constantly subjected to various mechanical forces, such as pulsatile blood flow, cyclic stretching, and vascular stiffening. These mechanical forces subjected on vSMCs and ECs must be balanced by opposite resistant forces, generated by the ECM and actomyosin-mediated contractility, which produces intracellular forces24,25. Mechanotransduction of these forces are dependent on cell–cell adherens junctions and cell-ECM adhesions26. Upon laminar flow, vSMCs and ECs sense and transduce the mechanical forces into biochemical signaling, thereby changing cellular behavior. Specifically for ECs, this includes alignment in the direction of blood flow and stabilization of adherens junctions27–29.
Interestingly, aorta pathology in MFS has been associated with endothelial dysfunction30–32. A characteristic of MFS is an increase in aortic stiffness, observed in MFS patients and in MFS mouse models33–37. Moreover, patients with MFS have elevated levels of von Willebrand factor and thrombomodulin, which are indicators of endothelial dysfunction38. Additionally, patients with MFS have impaired endothelial-dependent vasodilation, which is correlated with aortic aneurysm formation31,39,40. However, the effect of mutated FBN1 on EC morphology and the role of ECs during aortic pathogenesis in MFS is still unresolved.
Treatment with resveratrol (RESV) has been shown to exert vasoprotective effects41. As we reported earlier, two months RESV treatment halts aortic root dilatation in MFS mice by promoting elastin integrity and vSMC survival in part via its effect on ECs, producing an EC mediator that could downregulate detrimental vSMC-derived miR29b expression42. Moreover, RESV enhances endothelial nitric oxide (NO) production through upregulation of phospho-endothelial NO synthase (p-eNOS) expression and its subcellular localization on cell–cell contacts43,44. Yet, the direct effects of RESV on ECs, especially focusing on the morphological changes, remained unresolved.
In this study, we aim to elucidate the EC organization in a MFS mouse model. By using en face immunofluorescence (IF) visualization of ECs in the aorta of the Fbn1C1041G/+ MFS mouse model, we revealed an altered EC morphology in the thoracic ascending and descending aorta. Moreover, we describe the efficacy of RESV treatment on the normalization of EC morphology and number of elastin breaks in the aorta. The findings provide novel insights on the contribution of ECs to the aortic pathology in MFS and pinpoint the endothelial tissue as a potential novel therapeutic target for this rare disease.
Results
Morphological changes in aortic endothelial cells of MFS Fbn1C1041G/+ mice
We assessed the morphology of ECs in the ascending aorta, the location with frequent aortic aneurysms and dissections in MFS. To this end, transmembrane protein complexes of ECs were visualized by en face visualization of either VE-cadherin or β-catenin, which are both part of the same cell–cell junctional adhesion complex. In the outer curvature of the ascending aorta in 9 weeks old wild type (WT) mice, ECs were aligned with the direction of blood flow, characterized by elongated ECs, with the nucleus at the downstream side, and with straight cell–cell junctions (Fig. 1a). In contrast, the ECs in the outer curvature of the ascending aorta in 9 weeks old MFS Fbn1C1041G/+ mice appeared less elongated, more round in shape, with the nucleus more in the center of the EC, and not aligned with the blood flow as compared to WT (Fig. 1a). Aortic diameters were similar, indicating a pre-dilated state for the MFS mice. To methodologically assess morphological features, EC shapes were quantified based on five different parameters: alignment with flow, cell roundness, cell surface area, junctional linearity (i.e. junctional stability), and number of vertices (methodology illustrated in Fig. S1). This demonstrated that ECs in MFS mice show a substantial reduced alignment with flow, increased roundness of the cells, an enlarged cell surface area, a reduced junctional linearity index, while the number of vertices was similar between genotypes (Fig. 1b–f). The analysis of these parameters show that the ECs in the MFS ascending aorta demonstrate strong organizational changes that are present before dilatation occurs.
Milder effect of mutated FBN1 on EC morphology in thoracic descending aorta
We further assessed EC morphology in the thoracic descending aorta of the MFS mice. This region is not prone to aneurysm formation or dissections in this rodent model. As compared to WT and MFS ascending aorta (Fig. 1a), ECs from their respective genotypes were substantially less elongated and more round in shape in the descending aorta, probably attributed to the lower shear stress (Fig. S2). Comparing the descending aortae only, the aortic diameters were similar between WT and MFS as expected in this model (Fig. 2a). In the three-dimensional representation of the en face staining, a clear separation of the EC and vSMC layer can be observed (Movies S1, S2). Notably, the orientation of the vSMCs is perpendicular to the orientation of the ECs. The en face images showed subtle differences in the morphology of ECs between WT and MFS (Fig. 2a). Quantification of the EC morphology was performed using the five shape parameters (Fig. 2b–f). This revealed a substantial difference in the alignment of the ECs with the blood flow (Fig. 2b) and a substantial decrease in junctional linearity index (Fig. 2e). The latter was best observed in the ROI of the images, as EC junctions were straight in WT and jagged in MFS. Shape quantification in WT and MFS showed comparable cell roundness, surface area, and number of vertices. Taken together, endothelial disorganization is evident early in pathogenesis of MFS and particularly demarcates aneurysm-prone aortic locations.
EC alignment and junctional linearity aberrations in MFS ascending aorta ameliorated by resveratrol treatment
Subsequently, our experiments focused on the restoration of the EC organization in the aorta of the MFS model. Therefore, we therapeutically targeted ECs by administration of the polyphenol RESV in drinking water during three weeks to 36 weeks old Fbn1C1041G/+ MFS mice, which is at an age where the aortic pathology has been aggravated45.
Initially, the histology of the aorta in 36 weeks old Fbn1C1041G/+ MFS mice treated with either vehicle (MFS-CTRL) or RESV (MFS-RESV) was compared to untreated WT littermates. As expected at this age, the aortic root showed aneurysmal dilatation at 36 weeks in female Fbn1C1041G/+ MFS mice as compared to age and sex matched WT controls (Fig. S3A,B). The three week treatment with RESV in MFS mice did not change the enlarged diameter of the aortic root. The ascending aorta of MFS-CTRL and MFS-RESV mice showed no dilatation as compared to WT controls (Fig. S3C,D), which is common in this mild MFS model.
When focusing on the effect of RESV treatment on the EC morphology in the ascending aorta, we visualized EC adherens junctions using the en face IF method in 36 weeks old vehicle and RESV treated Fbn1C1041G/+ MFS mice. As these were older than the 9 weeks old mice used in the previous experiments, we first compared EC morphology between the 9 weeks old MFS mice with the 36 weeks old Fbn1C1041G/+ MFS mice. Due to ageing, we observed a further decline in junctional linearity and a reduction in cell surface area in the 36 weeks old MFS mice as compared to the 9 weeks old MFS mice (Fig. S4). The EC alignment with blood flow, number of vertices, and roundness remained similar during the pathogenic process (Fig. S4).
Next, we analyzed the effect of RESV treatment on the endothelium by comparing 36 weeks old MFS-CTRL with MFS-RESV. In the ascending aorta of vehicle treated Fbn1C1041G/+ MFS mice, ECs were round and not clearly aligned with the flow, where this seemed improved upon RESV treatment (Fig. 3a). Moreover, the junctions were more jagged in the MFS-CTRL, whereas junctions were more linear in the MFS-RESV. Quantification revealed that RESV indeed improved EC alignment with flow and increased the junctional linearity index (Fig. 3B,E). The roundness, cell surface area (Fig. 3C,D), and number of vertices (MFS-CTRL = 5.80 ± 0.35 vs MFS-RESV = 5.65 ± 0.23) remained unaltered.
As part of the RESV effect are mediated by eNOS46, we evaluated the expression of phosphorylated eNOS (p-eNOS) at serine 1177 in the ascending aorta. Specifically, we evaluated the expression of p-eNOS at the membrane junctions, as eNOS targeted to the plasma membrane generates the most NO47. In the ascending aorta of WT, higher levels of p-eNOS were present at cell–cell connections as compared to MFS-CTRL (Fig. 3f). Treatment with RESV reintroduced p-eNOS at the EC membrane. Quantification of p-eNOS on the cellular membrane showed restoration of p-eNOS fluorescence intensity in MFS-RESV for peak height and area under the curve (AUC), more closely resembling WT (Fig. 3g–i).
In addition, the EC morphology in the thoracic descending aorta of 36 weeks old Fbn1C1041G/+ MFS mice with RESV treatment was evaluated. Quantification of the EC morphological parameters revealed no substantial differences after RESV treatment in the descending aorta (Fig. S5). Therefore, the beneficial effects of RESV are mainly present in the disorganized EC features located in the ascending aorta.
Intercellular matrix alterations in MFS were improved by resveratrol treatment
A hallmark for thoracic aortic aneurysm formation in MFS is the high level of elastic lamina breaks. Therefore, we investigated the elastic lamina breaks using two methods. With a Lawson staining of aortic cross sections, the number of elastin breaks throughout the medial layer was determined. Complementary, with an en face approach the fraction of disrupted elastin in the internal elastic lamina (IEL), which forms the direct connection between the aortic intima (i.e. ECs) and media (i.e. vSMCs), was quantified.
To determine the number of elastin breaks in aortic cross sections, the Lawson staining was performed to reveal the elastic lamellae in the ascending aorta (Fig. 4a). In this aortic region, a substantial higher number of breaks in Fbn1C1041G/+ MFS mice was observed as compared to WT (Fig. 4b). After 3 weeks of RESV treatment, the number of elastin breaks in the aortic media of the ascending aorta in the MFS mice was not significantly reduced (p = 0.16).
Visualization of the IEL, which is the most luminal elastin sheet closest to the ECs, was performed based on the autofluorescent nature of the elastin protein. Data was acquired using an en face z-stack collection of confocal microscopy images capturing only the IEL. Subsequently, the maximal projection of the z-stack collection revealed the presence of disruptions (i.e. fenestrae) in the IEL. These were measured using a custom developed analysis pipeline in ImageJ software to quantify the level of elastin sheet disruptions (Fig. 4c). The total level of disrupted elastin was increased in the MFS mice as compared to WT (Fig. 4d,e). When focusing on the effect of RESV treatment on the disruption of the IEL, 36 weeks old MFS-CTRL were compared to MFS-RESV. This showed that the 3 week RESV treatment in MFS mice reduced the fraction of disrupted IEL (Fig. 4d,e), which indicates a partial restoration of the IEL integrity after RESV treatment. Potentially, the improved EC phenotype after RESV treatment is attributed to the combination of improved p-eNOS signaling and underlying elastin sheet repair that is achieved locally.
Discussion
In summary, these results show that the morphology of the ECs within the aorta of a representative model for MFS is altered and reveal that ECs may act as important mediator in the development of aorta pathology in MFS (Fig. 5). Specifically, EC alignment with flow, roundness, cell surface area, and junctional linearity were changed in the ascending aorta of MFS mice, when compared to age-matched WT littermates with similar aortic dimensions. This revealed for the first time that these endothelial changes occur prior to dilatation, suggesting a contributing role. In the thoracic descending aorta, which hardly shows aortic pathology in this MFS model, only the EC flow alignment and junctional linearity were reduced in MFS mice. This indicates that EC morphological alterations are more severe at the location where aortic aneurysms mostly occur, which is also the location subjected to enhanced mechanical forces.
The ECs emerged as target for RESV in our previous study, as RESV reduced aortic dilatation in an EC-dependent manner by decreasing the expression of aneurysm formation associated miR-29b in vSMCs42,48. Here, we attempt to unravel what effect RESV could have on the dysfunctional EC layer in the MFS aorta. Our data shows that RESV reversed the disturbed EC flow alignment, junctional linearity, p-eNOS expression, and integrity of the elastin sheet directly underneath the EC layer. Since fibrillin-1 is the core of elastin fibers and enhanced disruptions in the IEL adjacent to the endothelium were repaired upon RESV in MFS, this could be a direct consequence of the improved EC phenotype after RESV treatment. Potentially, reduced leakage of factors from the circulation or from dysfunctional ECs due to reduced elastin disruptions upon RESV, may also have a beneficial effect on the vSMC in the media. Our study extends current knowledge on aorta pathology in MFS and highlights the potential of targeting EC pathology to promote aortic health in MFS.
Recent clinical measurements on aortic blood flow dynamics in MFS patients revealed different flow patterns in the ascending aorta49–51. As the flow-derived forces (i.e. shear stress and circumferential stretch) have been shown to induce dynamic changes in EC shape and polarity52,53, this will lead to sustained and potentially progressive alterations in EC morphology. Functionally, impairment of flow-mediated EC-dependent vasodilation was described in MFS patients, which was correlated to aortic dilatation31, and can be attributed to disturbed anchoring of ECs to the subendothelial matrix54. Our data showed that the altered EC morphology was already observed before dilatation occurred, also suggesting that the effect of mutated FBN1 was perceived by ECs most probably due to alterations in the structure or composition of the intimal basement membrane and IEL. Our findings on the more disrupted IEL in the MFS model are in line with observation of López-Guimet et al.55, who also showed these disruptions in IEL structure by en face multiphoton microscopy. An increase in number and size of these fenestrae in the IEL has been linked to aortic aneurysm formation in mouse models55,56. The higher level of disruption in the IEL facilitates enhanced exchange of paracrine factors between the aortic intima and media through these fenestrae and enables more direct EC to vSMC contact57.
A combination of altered flow-derived forces and structural alterations in the ECM in MFS are translated into modified mechanoresponses in ECs. This modulates EC organization, EC shape, nuclear shape, and intracellular organelle positioning58,59. A recent study by Zhang et al.60 linked the formation of aortic aneurysms to defective mechanotransduction in ECs, due to distorted nuclear shape and positioning, and reduced EC flow alignment. An ECM-derived aspect participating in altered mechanoresponse is transforming growth factor-β (TGF-β), as fibrillin-1 plays a key role in sequestration of extracellular TGF-β, the EC-vSMC paracrine communication in MFS may involve changes for this growth factor61. As prolonged TGF-β signaling has been associated with endothelial dysfunction62, this could be as such partly responsible for the modified EC phenotype as well.
In the murine MFS model, we showed impaired EC alignment with flow in the ascending aorta and in the descending aorta, which is a morphological alteration similar as observed during disturbed flow at bifurcations and branch points throughout the vasculature63,64. In the descending aorta, the ECs appeared less stretched-out as compared to the ascending aorta, in line with previous in vitro observations due to lower shear stress65,66. Moreover, the reduced junctional linearity showed largest differences between WT and MFS, which has been observed in new forming or remodeling adherens junctions67,68. The linear junctions in WT ECs are considered as matured, show enhanced stability, and are attached to actin fibers that are oriented parallel to the cell–cell connection. The jagged junctions of MFS ECs are considered as immature, and connect to intracellular actin cytoskeletal stress fibers positioned mostly perpendicular to the cell membrane67,69. Impaired cell–cell junction linearization has been observed during development in a zebrafish model with induced compromised focal adhesion function, thereby linking defective cell-ECM to immature cell–cell connections70. Treatment with RESV induced partial preservation of EC alignment with flow, junctional linearity, and p-eNOS expression, which could also be linked to improved EC-ECM and EC-EC contacts.
Previously we showed that RESV reduced the aortic pathology in MFS mice42, and in this study we have provided more in depth understanding of the beneficial role that RESV can play to improve EC dysfunction and elastin structure. As RESV is a multi-target compound with many different mechanisms of actions71–74, not all pathways have been explored in this study to confirm direct or indirect targeting by RESV leading to improved p-eNOS and reduced elastin breaks. In previous research, the RESV effect on ECs and vSMCs are often referred as enhancing energy metabolism by upregulating sirtuin-1 and AMP-activated protein kinase activation75, reducing oxidative stress by NADPH oxidases76, upregulating endothelial NO production46, and reducing adherence of circulating monocytes77. While it has been shown that increased mitochondrial fitness and reducing NO-mediated stress decreases MFS aorta pathology78,79, yet the question remains how RESV, or one of its metabolites, accomplishes all the above effects and influences the various pathways.
Targeting the NO signaling pathway in MFS aortae has been shown to modulate aneurysm formation, although NOS isoform specific effects were observed80–82. When focusing on eNOS, it localizes at plasma membrane caveolae83, which is regulated by flow sensing84, therefore it seems that RESV also contributes to restoration of the mechanosensing through the caveolae in ECs85. Moreover, mechanosensing is associated with the YAP/TAZ transcription factor signaling pathway, which indicates that the effect of RESV on mechanosensing signaling pathways in MFS ECs can be further explored in future research.
MFS patients are often prescribed angiotensin-II receptor blockers (ARBs), of which losartan is most commonly used. Interestingly, ARBs have also been shown to have an angiotensin-II receptor independent protective function involving enhancement of EC function32,86,87, although treatment effects are diverse over the various FBN1 genotypes88 and for the various ARBs89. Moreover, ARBs were effective in reducing aneurysm formation in angiotensin-II receptor deficient mice by targeting EC function32. Since ARBs have been shown protective in MFS patients in the meta-analysis of most ARB clinical trials, a potential contributing mechanism is through modulation of ECs90. These data show that ECs may be a suitable target cell type in MFS aortic disease, since ECs are more readily in contact with circulating compounds than vSMCs.
In summary, our findings show that ECs in the pre-dilated aorta have morphological alterations in MFS mice, that were aggravated upon age. ECs act as target for RESV to restore EC morphology, p-eNOS expression, and aortic elastin integrity. In future work, the effects of RESV in a human MFS patient population should provide more insight on its effects on aortic functionality to combat cardiovascular complications91.
Methods
Animal models
Mice were maintained in accordance with the guidelines of the Amsterdam UMC location Academic Medical Center and the Directive 2010/63/EU of the European Parliament. Animal care and experimental procedures were approved by the independent animal experimental committee for Animal Welfare of the Academic Medical Center in Amsterdam. Fbn1C1041G/+ MFS mice on a C57Bl6 background were generated from a heterozygous breeding colony. Both male and female mice were included in this study on protocols DBC53AH-1, DBC18-4608-1-2 and -4. All experiments were in compliance with the ARRIVE guidelines. Details regarding the age of mice used in experiments are given in the description of results. Mice were anesthetized and euthanized by a single intraperitoneal injection of a cocktail containing 240 mg/kg ketamine and 24 mg/kg xylazine. The euthanized mice were exsanguinated and perfusion-fixed followed by collection of heart tissue and the thoracic aorta. The collected thoracic aortae contain the ascending aorta, arch, and proximal thoracic descending aorta. Tissues were fixed with 4% PFA in phosphate buffered saline (PBS) enriched with 1 mM CaCl2 and 0.5 mM MgCl2 (PBS++) and stored at 4 °C before further processing.
En face immunofluorescence staining and image acquisition
A small ring of the aorta was cut using precision scissors and tweezers (Fine Science Tools, Heidelberg, Germany) under a stereo microscope. The tissue ring was then cut open at the inner curvature. Subsequently, the rectangular aorta tissue was stretched and pinned down on a gel-coated petridish using small pins with the endothelium faced upwards. The aorta tissue was washed 3 times with PBS++ before permeabilization in 0.1% Triton-X in PBS++ for 15 min, followed by blocking of the tissue with a 2% bovine serum albumin (BSA) in PBS++ solution for 30 min. Primary antibodies were diluted in Pierce Immunostain Enhancer Solution (ThermoFisher) and incubation of the aorta tissue occurred for 1 h at room temperature. The following primary antibodies were used: polyclonal anti-VE-cadherin (#160840, Cayman Chemicals, Ann Arbor, MI, USA), mouse anti-β-Catenin (#610153, BD Bioscience, Franklin Lakes, NJ, USA), or rabbit anti-Phospho-eNOS (Ser1177) (#9570S, Cell signaling technology Danvers, MA, United States). Tissue was washed three times with PBST++ (PBS++ enriched with 0.1% Tween-20) followed by a 30 min incubation with 4’,6-diamidino-2-phenylindole (DAPI). Afterwards, Alexa-488 or Alexa-568 conjugated secondary antibodies (ThermoFisher) were diluted in Pierce Immunostain Enhancer Solution and tissue was incubated for 1 h. Optionally, phalloidin conjugated to Alexa-488 or Alexa-568 fluorophore (ThermoFisher) was added to the secondary antibody mix. After incubation, tissue was washed 3 times in PBST++ followed by a single wash step in H2O. To mount the tissue, pins were removed under a stereo microscope and the aortic tissue was stretched with the endothelium facing the cover glass. Tissue was mounted in Mowiol4-88/DABCO solution overnight with some light weights placed on top of the microscope glass to keep the tissue flattened. Images were acquired under a Leica TCS SP8 X coupled to a Leica DMI6000 confocal microscope equipped with a 63x/1.40 Oil CS2 objective. Determination of the aorta diameter was performed on the stretched-out aortic tissue samples after brightfield imaging.
Endothelial cell morphology and protein expression analysis
For all morphological parameters (Fig. S1), confocal images were analyzed using ImageJ software (National Institute of Health)92. Cell surface area and roundness were measured manually using the freehand selection tool with set measurements for area, perimeter and shape descriptors. Number of vertices was counted manually. The total length of straight lines between vertices was divided by the perimeter to obtain the junctional linearity index for a single EC. For each biological sample, at least four different images were analyzed. In every image at least 15 ECs were randomly selected for quantification. Quantification of p-eNOS on the cell–cell junction was performed using Leica Application Suite X software. Quantification was performed using a line segment with a length of at least 4 µm perpendicular over the cell junction. Background values were subtracted and normalized values were used to calculate peak height and AUC using Graphpad Prism 9.1 (La Jolla, CA, USA).
Histochemical staining and quantification
Aortic tissue was cut parallel to the aortic root before dehydration and embedding in paraffin to obtain optimal cross sections of the root and ascending aorta as described before93. Tissue slices were cut as 7 µm thick sections using a Microm HM340E microtome (ThermoFisher). After deparaffinization and rehydration, the hematoxylin and eosin (HE) staining or Lawson’s elastin staining were performed according to manufacturer’s procedure (Klinipath). Sections were imaged on a Leica DM6B light microscope. Measurements of the aorta root and ascending aorta diameter were performed on three different sections for each sample using the measure tool of Leica Application Suite X software (Leica). Number of elastin breaks was determined by manually counting the locations that showed a break in elastin fibers on a complete preparation. Three different sections for each sample were assessed by two independent blinded observers.
Internal elastic lamina disruption quantification
Determination of the fraction of disruption in the internal elastic lamina was performed using an en face method by imaging the autofluorescence signal of elastin fibers. Nuclei were counterstained with DAPI to determine the location within the sample. Images were acquired with a Leica TCS SP8 X confocal microscope coupled to a Leica DMI6000 camera. Specifically, only the first elastin sheet, which is located between the ECs of the intima and the first vSMC layer of the media, was imaged in z-stack mode and presented as maximum projection. Quantification of the data was performed using ImageJ software (National Institute of Health).
Statistical analyses
All data was processed and tested for significance using Graphpad Prism 9.1. All data is presented as mean ± SD, and number of ECs that were quantified described for each experiment. Threshold for significant difference was set at p < 0.05. In general, student’s t-test was used to compare the means of two groups and 1-way ANOVA was used to compare the means of more than two groups. Data distribution for EC flow alignment was tested by the Kolmogorov–Smirnov test.
Supplementary Information
Acknowledgements
We thank Myrthe Hoogeland for technical support on the histological examinations.
Author contributions
Conceptualization: A.M., M.v.d.S., S.H., V.d.W.; Methodology: M.v.d.S., T.v.K., V.d.W.; Software: A.M., M.v.d.S.; Formal analysis: A.M., M.v.d.S.; Investigation: A.M., M.v.d.S., S.L., E.C., T.v.K.; Data curation: A.M., M.v.d.S., S.H., V.d.W.; Writing—original draft: A.M., M.v.d.S.; Writing—review & editing: A.M., M.v.d.S., S.H., V.d.W.; Visualization: A.M.; Supervision: S.H., V.d.W.; Project administration: V.d.W.; Funding acquisition: V.d.W.
Funding
This work was financially supported by Health Holland TKI-Public Private Partnership grant 22532 to V.d.W.
Data availability
The raw data obtained during this study and processed data used for analysis is available upon reasonable request from the corresponding author.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Arnout Mieremet and Miesje van der Stoel.
These authors jointly supervised this work: Stephan Huveneers and Vivian de Waard.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-022-26662-5.
References
- 1.Pyeritz RE, McKusick VA. The Marfan syndrome: Diagnosis and management. N. Engl. J. Med. 1979;300:772–777. doi: 10.1056/nejm197904053001406. [DOI] [PubMed] [Google Scholar]
- 2.Loeys BL, et al. The revised Ghent nosology for the Marfan syndrome. J. Med. Genet. 2010;47:476–485. doi: 10.1136/jmg.2009.072785. [DOI] [PubMed] [Google Scholar]
- 3.Judge DP, Dietz HC. Marfan's syndrome. Lancet. 2005;366:1965–1976. doi: 10.1016/s0140-6736(05)67789-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Groth KA, et al. Prevalence, incidence, and age at diagnosis in Marfan Syndrome. Orphanet J. Rare Dis. 2015;10:153. doi: 10.1186/s13023-015-0369-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Milewicz DM, et al. Marfan syndrome. Nat. Rev. Dis. Prim. 2021;7:63. doi: 10.1038/s41572-021-00304-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Nollen GJ, Groenink M, van der Wall EE, Mulder BJ. Current insights in diagnosis and management of the cardiovascular complications of Marfan's syndrome. Cardiol. Young. 2002;12:320–327. doi: 10.1017/s1047951100012907. [DOI] [PubMed] [Google Scholar]
- 7.De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am. J. Med. Genet. 1996;62:417–426. doi: 10.1002/(sici)1096-8628(19960424)62:4<417::Aid-ajmg15>3.0.Co;2-r. [DOI] [PubMed] [Google Scholar]
- 8.Neptune ER, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 2003;33:407–411. doi: 10.1038/ng1116. [DOI] [PubMed] [Google Scholar]
- 9.Baumgartner H, et al. ESC guidelines for the management of adult congenital heart disease: the task force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD) Eur. Heart J. 2020;42:563–645. doi: 10.1093/eurheartj/ehaa554. [DOI] [PubMed] [Google Scholar]
- 10.Rock MJ, et al. Molecular basis of elastic fiber formation. Critical interactions and a tropoelastin-fibrillin-1 cross-link. J. Biol. Chem. 2004;279:23748–23758. doi: 10.1074/jbc.M400212200. [DOI] [PubMed] [Google Scholar]
- 11.Thomson J, et al. Fibrillin microfibrils and elastic fibre proteins: Functional interactions and extracellular regulation of growth factors. Semin. Cell Dev. Biol. 2019;89:109–117. doi: 10.1016/j.semcdb.2018.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Robinson PN, et al. The molecular genetics of Marfan syndrome and related disorders. J. Med. Genet. 2006;43:769. doi: 10.1136/jmg.2005.039669. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Jensen SA, Atwa O, Handford PA. Assembly assay identifies a critical region of human fibrillin-1 required for 10–12 nm diameter microfibril biogenesis. PLoS ONE. 2021;16:e0248532. doi: 10.1371/journal.pone.0248532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Godwin ARF, et al. The role of fibrillin and microfibril binding proteins in elastin and elastic fibre assembly. Matrix Biol. 2019;84:17–30. doi: 10.1016/j.matbio.2019.06.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Ramirez F, Caescu C, Wondimu E, Galatioto J. Marfan syndrome; A connective tissue disease at the crossroads of mechanotransduction, TGFβ signaling and cell stemness. Matrix Biol. 2018;71–72:82–89. doi: 10.1016/j.matbio.2017.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Holm TM, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332:358–361. doi: 10.1126/science.1192149. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Davis EC. Smooth muscle cell to elastic lamina connections in developing mouse aorta. Role in aortic medial organization. Lab. Invest. 1993;68:89–99. [PubMed] [Google Scholar]
- 18.Sakamoto H, et al. Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1. J. Biol. Chem. 1996;271:4916–4922. doi: 10.1074/jbc.271.9.4916. [DOI] [PubMed] [Google Scholar]
- 19.Lee SS, et al. Structure of the integrin binding fragment from fibrillin-1 gives new insights into microfibril organization. Structure. 2004;12:717–729. doi: 10.1016/j.str.2004.02.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Mariko B, et al. Microfibrils and fibrillin-1 induce integrin-mediated signaling, proliferation and migration in human endothelial cells. Am. J. Physiol. Cell Physiol. 2010;299:C977–C987. doi: 10.1152/ajpcell.00377.2009. [DOI] [PubMed] [Google Scholar]
- 21.Morsing SKH, et al. Double-hit–induced leukocyte extravasation driven by endothelial adherens junction destabilization. J. Immunol. 2020;205:511–520. doi: 10.4049/jimmunol.1900816. [DOI] [PubMed] [Google Scholar]
- 22.Milewicz DM, et al. Altered smooth muscle cell force generation as a driver of thoracic aortic aneurysms and dissections. Arterioscler. Thromb. Vasc. Biol. 2017;37:26–34. doi: 10.1161/ATVBAHA.116.303229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Zeyer KA, Zhang R-M, Kumra H, Hassan A, Reinhardt DP. The fibrillin-1 RGD integrin binding site regulates gene expression and cell function through microRNAs. J. Mol. Biol. 2019;431:401–421. doi: 10.1016/j.jmb.2018.11.021. [DOI] [PubMed] [Google Scholar]
- 24.Huveneers S, Daemen MJ, Hordijk PL. Between Rho(k) and a hard place: The relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. Circ. Res. 2015;116:895–908. doi: 10.1161/circresaha.116.305720. [DOI] [PubMed] [Google Scholar]
- 25.Charbonier FW, Zamani M, Huang NF. Endothelial cell mechanotransduction in the dynamic vascular environment. Adv. Biosyst. 2019;3:1800252. doi: 10.1002/adbi.201800252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Yamashiro Y, Yanagisawa H. The molecular mechanism of mechanotransduction in vascular homeostasis and disease. Clin. Sci. 2020;134:2399–2418. doi: 10.1042/cs20190488. [DOI] [PubMed] [Google Scholar]
- 27.Tzima E, et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature. 2005;437:426–431. doi: 10.1038/nature03952. [DOI] [PubMed] [Google Scholar]
- 28.Neto F, et al. YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development. Elife. 2018;7:e31037. doi: 10.7554/eLife.31037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Dejana E. Endothelial cell–cell junctions: Happy together. Nat. Rev. Mol. Cell Biol. 2004;5:261–270. doi: 10.1038/nrm1357. [DOI] [PubMed] [Google Scholar]
- 30.Lomelí O, et al. The evaluation of flow-mediated vasodilation in the brachial artery correlates with endothelial dysfunction evaluated by nitric oxide synthase metabolites in marfan syndrome patients. Front. Physiol. 2018 doi: 10.3389/fphys.2018.00965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Takata M, et al. Impairment of flow-mediated dilation correlates with aortic dilation in patients with Marfan syndrome. Heart Vessels. 2014;29:478–485. doi: 10.1007/s00380-013-0393-3. [DOI] [PubMed] [Google Scholar]
- 32.Sellers SL, et al. Inhibition of Marfan Syndrome aortic root dilation by losartan: Role of angiotensin II receptor type 1–independent activation of endothelial function. Am. J. Pathol. 2018;188:574–585. doi: 10.1016/j.ajpath.2017.11.006. [DOI] [PubMed] [Google Scholar]
- 33.Wanga S, et al. Aortic microcalcification is associated with elastin fragmentation in Marfan syndrome. J. Pathol. 2017;243:294–306. doi: 10.1002/path.4949. [DOI] [PubMed] [Google Scholar]
- 34.Sandor GG, et al. A novel Doppler echocardiographic method of measuring the biophysical properties of the aorta in pediatric patients. J. Am. Soc. Echocardiogr. 2003;16:745–750. doi: 10.1016/s0894-7317(03)00407-3. [DOI] [PubMed] [Google Scholar]
- 35.Crosas-Molist E, et al. Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome. Arterioscler. Thromb. Vasc. Biol. 2015;35:960–972. doi: 10.1161/atvbaha.114.304412. [DOI] [PubMed] [Google Scholar]
- 36.Bradley TJ, Potts JE, Potts MT, DeSouza AM, Sandor GG. Echocardiographic Doppler assessment of the biophysical properties of the aorta in pediatric patients with the Marfan syndrome. Am. J. Cardiol. 2005;96:1317–1321. doi: 10.1016/j.amjcard.2005.06.080. [DOI] [PubMed] [Google Scholar]
- 37.Vitarelli A, et al. Aortic wall mechanics in the Marfan syndrome assessed by transesophageal tissue Doppler echocardiography. Am. J. Cardiol. 2006;97:571–577. doi: 10.1016/j.amjcard.2005.09.089. [DOI] [PubMed] [Google Scholar]
- 38.Wilson JM, Ferguson JJ., 3rd Platelet-endothelial interactions in atherothrombotic disease: Therapeutic implications. Clin. Cardiol. 1999;22:687–698. doi: 10.1002/clc.4960221103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Chung AW, et al. Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome. Br. J. Pharmacol. 2007;150:1075–1083. doi: 10.1038/sj.bjp.0707181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Sheremet'eva GF, Ivanova AG, Belov Iu V, Gens AP, Kocharian EZ. A comparative study of the aortic wall in patients with Marfan's syndrome and Erdheim's disease. Angiol. Sosud. Khir. 2004;10:22–29. [PubMed] [Google Scholar]
- 41.Ungvari Z, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010;299:H18–H24. doi: 10.1152/ajpheart.00260.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Hibender S, et al. Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model. Arterioscler. Thromb. Vasc. Biol. 2016;36:1618–1626. doi: 10.1161/atvbaha.116.307841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Di Lorenzo A, et al. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. J. Cell Sci. 2013;126:5541–5552. doi: 10.1242/jcs.115972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Govers R, Bevers L, de Bree P, Rabelink TJ. Endothelial nitric oxide synthase activity is linked to its presence at cell–cell contacts. Biochem. J. 2002;361:193–201. doi: 10.1042/bj3610193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Habashi JP, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312:117–121. doi: 10.1126/science.1124287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Takahashi S, Nakashima Y. Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. Br. J. Nutr. 2012;107:774–780. doi: 10.1017/S0007114511003588. [DOI] [PubMed] [Google Scholar]
- 47.Boo YC, et al. Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic. Biol. Med. 2006;41:144–153. doi: 10.1016/j.freeradbiomed.2006.03.024. [DOI] [PubMed] [Google Scholar]
- 48.Merk DR, et al. miR-29b participates in early aneurysm development in Marfan syndrome. Circ. Res. 2012;110:312–324. doi: 10.1161/CIRCRESAHA.111.253740. [DOI] [PubMed] [Google Scholar]
- 49.Ruiz-Muñoz A, et al. Aortic flow dynamics and stiffness in Loeys–Dietz syndrome patients: a comparison with healthy volunteers and Marfan syndrome patients. Eur. Heart J. Cardiovasc. Imaging. 2021;23:641–649. doi: 10.1093/ehjci/jeab069. [DOI] [PubMed] [Google Scholar]
- 50.van Hout MJP, et al. Ascending aorta curvature and flow displacement are associated with accelerated aortic growth at long-term follow-up: A MRI study in Marfan and thoracic aortic aneurysm patients. IJC Heart Vasc. 2022;38:100926. doi: 10.1016/j.ijcha.2021.100926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Van Andel M, et al. Abnormal aortic hemodynamics at predilection sites for dissection in patients with Marfan syndrome: A 4D flow study. Eur. Heart J. Cardiovasc. Imaging. 2021 doi: 10.1093/ehjci/jeab090.067. [DOI] [Google Scholar]
- 52.Campinho P, Vilfan A, Vermot J. Blood flow forces in shaping the vascular system: A focus on endothelial cell behavior. Front. Physiol. 2020 doi: 10.3389/fphys.2020.00552. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Cybulsky MI, Marsden PA. Effect of disturbed blood flow on endothelial cell gene expression. Arterioscler. Thromb. Vasc. Biol. 2014;34:1806–1808. doi: 10.1161/ATVBAHA.114.304099. [DOI] [PubMed] [Google Scholar]
- 54.Wilson DG, et al. Endothelial function in Marfan syndrome. Circulation. 1999;99:909–915. doi: 10.1161/01.CIR.99.7.909. [DOI] [PubMed] [Google Scholar]
- 55.López-Guimet J, Andilla J, Loza-Alvarez P, Egea G. High-resolution morphological approach to analyse elastic laminae injuries of the ascending aorta in a murine model of Marfan syndrome. Sci. Rep. 2017;7:1–13. doi: 10.1038/s41598-017-01620-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Lee VS, et al. Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans. Proc. Natl. Acad. Sci. 2016;113:8759–8764. doi: 10.1073/pnas.1601442113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Méndez-Barbero N, Gutiérrez-Muñoz C, Blanco-Colio LM. Cellular crosstalk between endothelial and smooth muscle cells in vascular wall remodeling. Int. J. Mol. Sci. 2021;22:7284. doi: 10.3390/ijms22147284. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Salvador J, Iruela-Arispe ML. Nuclear mechanosensation and mechanotransduction in vascular cells. Front. Cell Dev. Biol. 2022 doi: 10.3389/fcell.2022.905927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Tkachenko E, et al. The nucleus of endothelial cell as a sensor of blood flow direction. Biol. Open. 2013;2:1007–1012. doi: 10.1242/bio.20134622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Zhang Y, et al. The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inflammation and the formation of abdominal aortic aneurysms. bioRxiv. 2021 doi: 10.1101/2021.05.07.443138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Matt P, et al. Circulating transforming growth factor-β in Marfan syndrome. Circulation. 2009;120:526–532. doi: 10.1161/CIRCULATIONAHA.108.841981. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Zhu J, et al. Loss of transforming growth factor beta signaling in aortic smooth muscle cells causes endothelial dysfunction and aortic hypercontractility. Arterioscler. Thromb. Vasc. Biol. 2021;41:1956–1971. doi: 10.1161/ATVBAHA.121.315878. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Davies PF. Flow-mediated endothelial mechanotransduction. Physiol. Rev. 1995;75:519–560. doi: 10.1152/physrev.1995.75.3.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Chiu J-J, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol. Rev. 2011;91:327–387. doi: 10.1152/physrev.00047.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Suna Y, Zhanga B, Xiaa L. Effect of low wall shear stress on the morphology of endothelial cells and its evaluation indicators. Comput. Methods Progr. Biomed. 2021;208:106082. doi: 10.1016/j.cmpb.2021.106082. [DOI] [PubMed] [Google Scholar]
- 66.Rampersad SN, et al. EPAC1 promotes adaptive responses in human arterial endothelial cells subjected to low levels of laminar fluid shear stress: Implications in flow-related endothelial dysfunction. Cell. Signal. 2016;28:606–619. doi: 10.1016/j.cellsig.2016.02.016. [DOI] [PubMed] [Google Scholar]
- 67.Angulo-Urarte A, van der Wal T, Huveneers S. Cell-cell junctions as sensors and transducers of mechanical forces. Biochim. Biophys. Acta (BBA) Biomembr. 2020;1862:183316. doi: 10.1016/j.bbamem.2020.183316. [DOI] [PubMed] [Google Scholar]
- 68.Lagendijk AK, et al. Live imaging molecular changes in junctional tension upon VE-cadherin in zebrafish. Nat. Commun. 2017;8:1402. doi: 10.1038/s41467-017-01325-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Millán J, et al. Adherens junctions connect stress fibres between adjacent endothelial cells. BMC Biol. 2010;8:11. doi: 10.1186/1741-7007-8-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Chau TC, et al. Dynamically regulated Focal adhesions coordinate endothelial cell remodelling in developing vasculature. bioRxiv. 2022 doi: 10.1101/2022.02.01.478747. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Xia N, Daiber A, Förstermann U, Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 2017;174:1633–1646. doi: 10.1111/bph.13492. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Cheng CK, et al. Pharmacological basis and new insights of resveratrol action in the cardiovascular system. Br. J. Pharmacol. 2020;177:1258–1277. doi: 10.1111/bph.14801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Parsamanesh N, et al. Resveratrol and endothelial function: A literature review. Pharmacol. Res. 2021;170:105725. doi: 10.1016/j.phrs.2021.105725. [DOI] [PubMed] [Google Scholar]
- 74.van Andel MM, Groenink M, Zwinderman AH, Mulder BJM, de Waard V. The potential beneficial effects of resveratrol on cardiovascular complications in Marfan syndrome patients–insights from rodent-based animal studies. Int. J. Mol. Sci. 2019 doi: 10.3390/ijms20051122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Price NL, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15:675–690. doi: 10.1016/j.cmet.2012.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function. Arterioscler. Thromb. Vasc. Biol. 2009;29:1164–1171. doi: 10.1161/ATVBAHA.109.187146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Cicha I, et al. Shear stress preconditioning modulates endothelial susceptibility to circulating TNF-α and monocytic cell recruitment in a simplified model of arterial bifurcations. Atherosclerosis. 2009;207:93–102. doi: 10.1016/j.atherosclerosis.2009.04.034. [DOI] [PubMed] [Google Scholar]
- 78.Oller J, et al. Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome. Nat. Med. 2017;23:200–212. doi: 10.1038/nm.4266. [DOI] [PubMed] [Google Scholar]
- 79.Oller J, et al. Extracellular tuning of mitochondrial respiration leads to aortic aneurysm. Circulation. 2021;143:2091–2109. doi: 10.1161/CIRCULATIONAHA.120.051171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Huang K, Wang Y, Siu KL, Zhang Y, Cai H. Targeting feed-forward signaling of TGFβ/NOX4/DHFR/eNOS uncoupling/TGFβ axis with anti-TGFβ and folic acid attenuates formation of aortic aneurysms: Novel mechanisms and therapeutics. Redox Biol. 2021;38:101757. doi: 10.1016/j.redox.2020.101757. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.de la Fuente-Alonso A, et al. Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO. Nat. Commun. 2021;12:2628. doi: 10.1038/s41467-021-22933-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Nettersheim FS, et al. Nitro-oleic acid reduces thoracic aortic aneurysm progression in a mouse model of Marfan syndrome. Cardiovasc. Res. 2021;118:2211–2225. doi: 10.1093/cvr/cvab256. [DOI] [PubMed] [Google Scholar]
- 83.Shaul PW. Regulation of endothelial nitric oxide synthase: Location, location, location. Annu. Rev. Physiol. 2002;64:749–774. doi: 10.1146/annurev.physiol.64.081501.155952. [DOI] [PubMed] [Google Scholar]
- 84.Yu J, et al. Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J. Clin. Investig. 2006;116:1284–1291. doi: 10.1172/JCI27100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Klinge CM, Wickramasinghe NS, Ivanova MM, Dougherty SM. Resveratrol stimulates nitric oxide production by increasing estrogen receptor αa-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells. FASEB J. 2008;22:2185–2197. doi: 10.1096/fj.07-103366. [DOI] [PubMed] [Google Scholar]
- 86.Watanabe T, et al. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: Angiotensin II type 1 receptor-independent effects of EXP3179. Circulation. 2005;112:1798–1805. doi: 10.1161/circulationaha.104.509760. [DOI] [PubMed] [Google Scholar]
- 87.Tehrani AY, et al. Blood pressure-independent inhibition of Marfan aortic root widening by the angiotensin II receptor blocker valsartan. Physiol. Rep. 2021;9:e14877. doi: 10.14814/phy2.14877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Franken R, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ. Cardiovasc. Genet. 2015;8:383–388. doi: 10.1161/CIRCGENETICS.114.000950. [DOI] [PubMed] [Google Scholar]
- 89.Tehrani AY, et al. Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects. Sci. Rep. 2022;12:9771. doi: 10.1038/s41598-022-13772-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Pitcher A, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: An individual patient data meta-analysis of randomised trials. The Lancet. 2022;400:822–831. doi: 10.1016/S0140-6736(22)01534-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.van Andel, M. M. et al. The effect of resveratrol on aortic function in patients with Marfan syndrome–rationale and design of the resvcue Marfan trial. PREPRINT (Version 1) available at Research Square10.21203/rs.3.rs-434876/v1 (2021).
- 92.Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671–675. doi: 10.1038/nmeth.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Franken R, et al. No beneficial effect of general and specific anti-inflammatory therapies on aortic dilatation in Marfan mice. PLoS ONE. 2014;9:e107221. doi: 10.1371/journal.pone.0107221. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The raw data obtained during this study and processed data used for analysis is available upon reasonable request from the corresponding author.